87486-34-8 Archives - Page 5 of 9

Currie, Kevin S. et al. published their patent in 2012 |CAS: 87486-34-8

The Article related to preparation pyridinone pyrazinone btk kinase inhibitor therapy diagnosis, immune disorder treatment pyridinone pyrazinone btk kinase inhibitor, inflammation cancer treatment pyridinone pyrazinone btk kinase inhibitor and other aspects.Product Details of 87486-34-8

On March 8, 2012, Currie, Kevin S.; Wang, Xiaojing; Young, Wendy B. published a patent.Product Details of 87486-34-8 The title of the patent was Preparation of pyridinones and pyrazinones as Btk kinase inhibitors for treating inflammation, immunological disorders, cancer, and other diseases. And the patent contained the following:

Pyridinone and pyrazinone compounds of Formula I (wherein R1 is substituted isoindolinone, thienopyrrolone, or pyrrolothiazolone; R2 is H, Me, or CF3; ring B is ring B is Ph, 5-6 membered heteroaryl, or 8-11 membered heterocyclyl; R3 is H, halo, cyano, etc.; R6 is H, Me, F, etc.; R7 is H, Me F, etc.; R8 is H, Me, CF3, etc.; V is CH or N) including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase are claimed. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathol. conditions, are disclosed. Synthetic procedures for preparing I are exemplified. Example compound II, prepared in a multistep synthesis that culminated in the cyclization of III, had an IC50 of 0.0364 in a standard biochem. Btk kinase assay. The experimental process involved the reaction of 3,5-Dibromo-1-methylpyrazin-2(1H)-one(cas: 87486-34-8).Product Details of 87486-34-8

Referemce:
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem

Barbosa, Antonio J. M. et al. published their patent in 2011 |CAS: 87486-34-8

The Article related to pyridone azapyridone preparation btk inhibitor immune disease inflamation cancer, benzothienopyridinone pyrazinoindolone pyrazinobenzimidazolone methanopyrazinoindolone preparation rheumatoid arthritis and other aspects.Reference of 3,5-Dibromo-1-methylpyrazin-2(1H)-one

On November 10, 2011, Barbosa, Antonio J. M.; Blomgren, Peter A.; Currie, Kevin S.; Krishnamoorthy, Ravi; Kropf, Jeffrey E.; Lee, Seung H.; Mitchell, Scott A.; Ortwine, Daniel; Schmitt, Aaron C.; Wang, Xiaojing; Xu, Jianjun; Young, Wendy; Zhang, Honglu; Zhao, Zhongdong; Zhichkin, Pavel E. published a patent.Reference of 3,5-Dibromo-1-methylpyrazin-2(1H)-one The title of the patent was Preparation of pyridone and azapyridone compounds as Btk inhibitors for treating immune disorders, inflammation, cancer, and other Btk-mediated diseases. And the patent contained the following:

The invention is related to the preparation of pyridones and azapyridones I [R1 = H, D, F, CN, OH, etc.; R2-4 = independently alkyl, Cl, NH2, OEt, etc.; R5 = (un)substituted (hetero)aryl, carbocyclyl, etc.; X = (S)0-2, N, NR6, O, CH and derivatives; R6 = H, F, NH2, OH, (un)substituted alkyl; Y, Y’ = independently CR6, N; Z1-4 = independently C, CH and derivatives, N; Z5 = CO, CH2 and derivatives, CH:N and derivatives, NH and derivatives, etc.; one of Z1 and Z2 or X and Z1, where X is not (S)0-2, forms a 5-7 membered aryl, carbocyclyl, heterocyclyl, heteroaryl ring; where alkyl, aryl, carbocyclyl, heterocyclyl, heteroaryl are optionally substituted] their stereoisomers, tautomers, and pharmaceutically acceptable salts useful for inhibiting Btk kinase, and for treating immune disorders, inflammation, cancer, and other Btk-mediated diseases. Methods of using I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathol. conditions, are disclosed. Thus, a multi-step synthesis starting from 5-nitropyrazole-3-carboxylic acid via cyclization of 1-(2-Bromoethyl)-5-(bromomethyl)-3-nitro-1H-pyrazole to 5-Methyl-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine and cyclization of Et 1-(2-Aminoethyl)-4,5,6,7-tetrahydro-1H-indole-2-carboxylate to 3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one was given for II. II inhibited Btk kinase (IC50 = 0.002 μM). The experimental process involved the reaction of 3,5-Dibromo-1-methylpyrazin-2(1H)-one(cas: 87486-34-8).Reference of 3,5-Dibromo-1-methylpyrazin-2(1H)-one

Referemce:
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem

Young, Wendy B. et al. published their research in Bioorganic & Medicinal Chemistry Letters in 2015 |CAS: 87486-34-8

The Article related to bruton tyrosine kinase inhibitor gdc0834 preparation structure activity pharmacokinetics, amide hydrolysis, bruton’s tyrosine kinase, btk, gdc-0834, kinase inhibitor, rheumatoid arthritis, single dose ind and other aspects.Recommanded Product: 87486-34-8

On March 15, 2015, Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Gallion, Steve; Hymowitz, Sarah G.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Maurer, Brigitte; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Sowell, C. Gregory; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Zhao, Zhongdong; Currie, Kevin S. published an article.Recommanded Product: 87486-34-8 The title of the article was Potent and selective Bruton’s tyrosine kinase inhibitors: Discovery of GDC-0834. And the article contained the following:

SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 resulted in the clin. candidate GDC-0834, which retained the potency and selectivity of CGI-1746, but with much improved PK in preclin. animal models. Structure based design efforts drove this work as modifications to CGI-1746 were investigated at both the solvent exposed region as well as ‘H3 binding pocket’. However, in vitro metabolic evaluation of GDC-0834 revealed a non CYP-mediated metabolic process that was more prevalent in human than preclin. species (mouse, rat, dog, cyno), leading to a high-level of uncertainly in predicting human pharmacokinetics. Due to its promising potency, selectivity, and preclin. efficacy, a single dose IND was filed and GDC-0834 was taken in to a single dose phase I trial in healthy volunteers to quickly evaluate the human pharmacokinetics. In human, GDC-0834 was found to be highly labile at the exo-cyclic amide bond that links the tetrahydrobenzothiophene moiety to the central aniline ring, resulting in insufficient parent drug exposure. This information informed the back-up program and discovery of improved inhibitors. The experimental process involved the reaction of 3,5-Dibromo-1-methylpyrazin-2(1H)-one(cas: 87486-34-8).Recommanded Product: 87486-34-8

Referemce:
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem

29-Sep News Brief introduction of 87486-34-8

Chemical properties determine the actual use. Each compound has specific chemical properties and uses. We look forward to more synthetic routes in the future to expand reaction routes of 87486-34-8.

87486-34-8, Adding some certain compound to certain chemical reactions, such as: 87486-34-8, name is 3,5-Dibromo-1-methylpyrazin-2(1H)-one, can increase the reaction rate and produce products with better performance than those obtained under traditional synthetic methods. Here is a downstream synthesis route of the compound 87486-34-8.

A solution of 3,5-dibromo-1-methylpyrazin-2-one (500.0 mg, 2.46 mmol), NH3H2O (5.0 mL) in dioxane (30.0 mL) was heated at 105° C. for 20 h. The mixture was concentrated, diluted with EtOAc (50 mL) and filtrated to give the title compound (300.0 mg, 79.0percent) which was carried on without purification. LCMS (M+H)+ 204.

Chemical properties determine the actual use. Each compound has specific chemical properties and uses. We look forward to more synthetic routes in the future to expand reaction routes of 87486-34-8.

Reference:
Patent; Bennett, Michael John; Betancort, Juan Manuel; Boloor, Amogh; Kaldor, Stephen W.; Stafford, Jeffrey Alan; Veal, James Marvin; US2015/111885; (2015); A1;,
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem

September 28, 2021 News Share a compound : 87486-34-8

The synthetic route of 87486-34-8 has been constantly updated, and we look forward to future research findings.

Electric Literature of 87486-34-8, A common heterocyclic compound, 87486-34-8, name is 3,5-Dibromo-1-methylpyrazin-2(1H)-one, molecular formula is C5H4Br2N2O, its traditional synthetic route has been very mature, but the traditional synthetic route has various shortcomings, such as complicated route, low yield, poor purity, etc, below Introduce a new synthetic route.

Example 17 A solution of the aminopyrazole (0.28 g, 2.5 mmol) and the dibromopyrazinone (0.74 g, 1.1 equiv) were heated to 120° C. in isopropanol for 1 h. The reaction mixture was cooled to RT, and the product was isolated by filtration (0.43 g, 57percent).

The synthetic route of 87486-34-8 has been constantly updated, and we look forward to future research findings.

Reference:
Patent; Roche Palo Alto LLC; US2010/4231; (2010); A1;,
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem

Sep-21 News The important role of 87486-34-8

If you are interested in these compounds, you can also browse my other articles.Thank you for taking the time to read this article. I hope you enjoyed it.

Adding a certain compound to certain chemical reactions, such as: 87486-34-8, name is 3,5-Dibromo-1-methylpyrazin-2(1H)-one, belongs to pyrazines compound, can increase the reaction rate and produce products with better performance than those obtained under traditional synthetic methods. Here is a downstream synthesis route of the compound 87486-34-8, Product Details of 87486-34-8

Example 186a 5-Bromo-1-methyl-3-(pyridin-3-ylamino)pyrazin-2(1H)-one 186a A 100-mL single-neck round-bottomed flask equipped with a magnetic stirrer and a reflux condenser was charged with pyridin-3-amine (940 mg, 10 mmol), 3,5-dibromo-1-methylpyrazin-2(1H)-one (5.4 g, 20 mmol), i-propanol (50 mL), and di-i-propylethylamine (10 mL). The mixture was heated at reflux for 5 h. After the completion of the reaction, it was cooled to room temperature. The solvent was removed under reduced pressure. The crude was purified by silica-gel column chromatography eluting with 30:1 dichloromethane/methanol to afford 186a (1.4 g, 50percent) as a yellow solid. MS-ESI: [M+H]+ 281.6.

If you are interested in these compounds, you can also browse my other articles.Thank you for taking the time to read this article. I hope you enjoyed it.

Reference:
Patent; F.Hoffmann-La Roche AG; CRAWFORD, James John; ORTWINE, Daniel Fred; WEI, BinQing; YOUNG, Wendy B.; EP2773638; (2015); B1;,
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem

S News Extended knowledge of 87486-34-8

The synthetic route of 87486-34-8 has been constantly updated, and we look forward to future research findings.

87486-34-8, name is 3,5-Dibromo-1-methylpyrazin-2(1H)-one, belongs to pyrazines compound, is considered to be a conventional heterocyclic compound, which is widely used in drug synthesis. The chemical synthesis route is as follows. HPLC of Formula: C5H4Br2N2O

Example 123c 5-Bromo-3-(1-ethyl-1H-pyrazol-4-ylamino)-1-methylpyrazin-2(1H)-one 123c A 100-mL single-neck round-bottomed flask equipped with a magnetic stirrer and reflux condenser was charged with 123b (500 mg, 4.5 mmol), 3,5-dibromo-1-methylpyrazin-2(1H)-one (2.40 g, 9.0 mmol), DIPethyl acetate (3 mL), and isopropanol (50 mL). The mixture was heated at 100° C. for 2 h. It was then cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure to afford 123c (802 mg, 60percent) as a white solid. MS-ESI: [M+H]+ 298.0

The synthetic route of 87486-34-8 has been constantly updated, and we look forward to future research findings.

Reference:
Patent; GENENTECH, INC.; Crawford, James John; Ortwine, Daniel Fred; Wei, BinQing; Young, Wendy B.; US2013/116246; (2013); A1;,
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem

10-Sep-21 News Continuously updated synthesis method about 87486-34-8

These compound has a wide range of applications. It is believed that with the continuous development of the source of the synthetic route 3,5-Dibromo-1-methylpyrazin-2(1H)-one, its application will become more common.

Reference of 87486-34-8,Some common heterocyclic compound, 87486-34-8, name is 3,5-Dibromo-1-methylpyrazin-2(1H)-one, molecular formula is C5H4Br2N2O, traditional synthetic route has been very mature, but the traditional synthetic route has various shortcomings, such as complicated route, low yield, poor purity, etc, below Introduce a new synthetic route.

Example 109c 5-Bromo-3-(l-cyclopropyl-lH-pyrazol-4-ylamino)-l-methylpyrazin- -one 109cCGIPHARM60WOA 100-mL three-neck round-bottomed flask equipped with a reflux condenser, magnetic stirrer and nitrogen inlet was charged with 109b (378 mg, 3.07 mmol), 3,5- dibromo-l-methylpyrazin-2(lH)-one (906 mg, 3.38 mmol), cesium carbonate (3.00 g, 9.21 mmol), and 1,4-dioxane (45 mL). After bubbling nitrogen through the resulting suspension for 30 min, Xantphos (151 mg, 0.261 mmol) and tris(dibenzylidene-acetone)dipalladium(0) (141 mg, 0.154 mmol) were added, and the reaction mixture was heated at reflux for 3 h. After this time, the mixture was cooled to room tempera-ture and diluted with ethyl acetate (150 mL) and water (30 mL). The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3 x 45 mL). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (silica, 0percent to 10percent methanol/methylene chloride) to afford a 28percent yield (266 mg) of 109c as an off-white solid: mp 228-230 °C; ]H NMR (300 MHz, DMSO-i3/4) delta 9.90 (s, 1H), 8.06 (s, 1H), 7.69 (s, 1H), 7.21 (s, 1H), 3.70 (m, 1H), 3.41 (s, 3H), 0.96 (m, 4H); MS (ESI+) m/z 310.0 (M+H).

Reference:
Patent; GILEAD CONNECTICUT, INC.; GENENTECH, INC.; CURRIE, Kevin S.; WANG, Xiaojing; YOUNG, Wendy B.; WO2012/31004; (2012); A1;,
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem

9/9/2021 News The origin of a common compound about 87486-34-8

The synthetic route of 3,5-Dibromo-1-methylpyrazin-2(1H)-one has been constantly updated, and we look forward to future research findings.

Related Products of 87486-34-8, In the next few decades, the world population will flourish. As the population grows rapidly and people all over the world use more and more resources, all industries must consider their environmental impact. 87486-34-8, name is 3,5-Dibromo-1-methylpyrazin-2(1H)-one belongs to pyrazines compound, it is a common compound, a new synthetic route is introduced below.

General procedure: To a solution of 2a-j (10 mmol, 1.0 eq) , 3,5-dibromo-1-methylpyrazin-2(1H)-one (2.95 g, 11 mmol, 1.1 eq) and DIEA (3.3 mL,20 mmol, 2.0 eq) in MeCN (20mL) was stirred at 80 °C for 5 hours. After cooling to room temperature, thesolvent was removed in vacuo, and the residue was purified using silica gelchromatography to give the title compounds, yield 72-85percent.

The synthetic route of 3,5-Dibromo-1-methylpyrazin-2(1H)-one has been constantly updated, and we look forward to future research findings.

Reference:
Article; Yang, Jianhong; Du, Jiatian; Huang, Chong; Wang, Tianqi; Huang, Luyi; Yang, Shengyong; Li, Linli; Bioorganic and Medicinal Chemistry Letters; vol. 29; 13; (2019); p. 1609 – 1613;,
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem

9/2/2021 News Simple exploration of 87486-34-8

The synthetic route of 87486-34-8 has been constantly updated, and we look forward to future research findings.

A mixture of tert-butyl 4-(4-aminophenyl)piperidine-l-carboxylate (2.5 g, 9.06 mmol) and 3,5-dibromo-l-methylpyrazin-2(lH)-one (2.2 g, 8.23 mmol) in isopropanol (30 mL) was heated at 85 °C for 15 h. After the reaction was finished, it was filtered and the solid was washed with isopropanol to afford 282a as a white solid (2.9 g, 80 ).LCMS: (M+H)+ 463

The synthetic route of 87486-34-8 has been constantly updated, and we look forward to future research findings.

Reference:
Patent; GILEAD CONNECTICUT, INC.; GENENTECH, INC.; BARBOSA, Antonio, J., M.; BLOMGREN, Peter, A.; CURRIE, Kevin, S.; KRISHNAMOORTHY, Ravi; KROPF, Jeffrey, E.; LEE, Seung H.; MITCHELL, Scott A.; ORTWINE, Daniel; SCHMITT, Aaron, C.; WANG, Xiaojing; XU, Jianjun; YOUNG, Wendy; ZHANG, Honglu; ZHAO, Zhongdong; ZHICHKIN, Pavel E.; WO2011/140488; (2011); A1;,
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem